Key facts
- Five EU countries (Belgium, Netherlands, Luxembourg, Austria, Ireland) are advocating for a unified European response to drug pricing pressures.
- They warn that uncoordinated national actions could be detrimental in the face of U.S. demands for higher medicine prices.
- The U.S. administration is reportedly negotiating bilateral drug pricing deals with European nations.
- Pharmaceutical companies, including Pfizer, have expressed concerns about potential investment impacts due to planned price reductions in countries like Germany.
- EU ministers are set to discuss these pressures at an upcoming meeting, with divisions apparent among member states.
Five European Union member states have called for a united front in negotiating drug prices, urging an end to uncoordinated national responses to pressure from the United States and pharmaceutical companies. Belgium, the Netherlands, Luxembourg, Austria, and Ireland, part of the Beneluxa initiative, stated that collaboration is essential to address shared challenges in the pharmaceutical sector.
This joint appeal comes as the U.S. administration reportedly tasks its embassies across Europe with negotiating national drug pricing deals, similar to an agreement with the U.K. where higher prices were accepted to avoid tariffs. Pharmaceutical executives, including Pfizer CEO Albert Bourla, have engaged with European leaders, such as German Chancellor Friedrich Merz, expressing concerns that planned price reductions could impact investments. Companies like Eli Lilly and Boehringer Ingelheim have already paused German investments.
Despite health policy being a national competence within the EU, the Beneluxa group argues that "streamlining [pricing and reimbursement] procedures on a mutually agreed collaborative basis" would foster a more unified European approach. They emphasize the need for sustainable medicine expenditure to ensure future patient access.
EU ministers are scheduled to discuss these issues, with indications of differing viewpoints among member states. Sweden has also initiated discussions on a coordinated response to geopolitical challenges in the pharma sector. Meanwhile, the generics industry suggests that promoting off-patent alternatives could save the EU significant funds, which could then be allocated to other medicines.
The European Commission's proposal to extend patent rights for certain biotech medicines, contingent on European manufacturing, has drawn criticism from public payers, patient groups, and the generics industry, who warn it will increase costs. The European Parliament is pursuing its own study on the potential impact of this proposal on national health budgets.